KAV, T. Et Al. 2017. Azelnidipine, a novel calcium channel blocker, ameliorates severity of colitis in DSS induced colitis in mice possibly by modulating tissue levels of TNF-alpha and IL-6. 12th Congress of ECCO , (Barselona, Spain), 93-94.

KAV, T., AKYOL, A., KAHRAMANOĞLU AKSOY, E., ÖZER, C., TORGUTALP, M., & SİVRİ, B., (2017). Azelnidipine, a novel calcium channel blocker, ameliorates severity of colitis in DSS induced colitis in mice possibly by modulating tissue levels of TNF-alpha and IL-6 . 12th Congress of ECCO (pp.93-94). Barselona, Spain

KAV, TAYLAN Et Al. "Azelnidipine, a novel calcium channel blocker, ameliorates severity of colitis in DSS induced colitis in mice possibly by modulating tissue levels of TNF-alpha and IL-6," 12th Congress of ECCO, Barselona, Spain, 2017

KAV, TAYLAN Et Al. "Azelnidipine, a novel calcium channel blocker, ameliorates severity of colitis in DSS induced colitis in mice possibly by modulating tissue levels of TNF-alpha and IL-6." 12th Congress of ECCO , Barselona, Spain, pp.93-94, 2017

KAV, T. Et Al. (2017) . "Azelnidipine, a novel calcium channel blocker, ameliorates severity of colitis in DSS induced colitis in mice possibly by modulating tissue levels of TNF-alpha and IL-6." 12th Congress of ECCO , Barselona, Spain, pp.93-94.

@conferencepaper{conferencepaper, author={TAYLAN KAV Et Al. }, title={Azelnidipine, a novel calcium channel blocker, ameliorates severity of colitis in DSS induced colitis in mice possibly by modulating tissue levels of TNF-alpha and IL-6}, congress name={12th Congress of ECCO}, city={Barselona}, country={Spain}, year={2017}, pages={93-94} }